

N.B. English translation is for convenience purposes only

**The Board of Directors' of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, proposal to amend the articles of association (item 7)**

---

The Board of Directors proposes that the Extraordinary General Meeting resolves to amend the limits of the share capital and the number of shares in the articles of association.

Item 4 in the articles of association is proposed to be amended from:

*"The share capital shall be not less than SEK 2,500,000 and not more than SEK 10,000,000."* to:

*"The share capital shall be not less than SEK 4,500,000 and not more than SEK 18,000,000."*

Item 5 in the articles of association is proposed to be amended from:

*"The number of shares shall be not less than 50,000,000 and not more than 200,000,000."* to:

*"The number of shares shall be not less than 90,000,000 and not more than 360,000,000."*

The CEO, or any other person appointed by the Board of Directors, shall have the right to make such minor adjustments that may be required in order to register the resolution with the Swedish Companies Registration Office.

A resolution in accordance with the Board of Directors' proposal shall be conditional upon that the Extraordinary General Meeting has approved the Board of Directors' resolution to issue shares with preferential rights for existing shareholders in accordance with item 6.

A valid resolution in accordance with the Board of Directors' proposal according to above requires the approval of shareholders representing at least two thirds of the votes cast and the shares represented at the Extraordinary General Meeting.

---

Lund in December 2018

**NeuroVive Pharmaceutical AB (publ)**

*The Board of Directors*